- Home
- CRNX vs CANF Comparison
CRNX vs CANF Comparison
Compare CRNX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- CANF
- Stock Information
- Founded
- CRNX 2008
- CANF 1994
- Country
- CRNX United States
- CANF Israel
- Employees
- CRNX N/A
- CANF N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- CANF Health Care
- Exchange
- CRNX Nasdaq
- CANF Nasdaq
- Market Cap
- CRNX N/A
- CANF 7.9M
- IPO Year
- CRNX 2018
- CANF N/A
- Fundamental
- Price
- CRNX $30.42
- CANF $1.20
- Analyst Decision
- CRNX Strong Buy
- CANF Strong Buy
- Analyst Count
- CRNX 12
- CANF 2
- Target Price
- CRNX $73.36
- CANF $14.00
- AVG Volume (30 Days)
- CRNX 1.2M
- CANF 413.8K
- Earning Date
- CRNX 05-08-2025
- CANF 04-29-2025
- Dividend Yield
- CRNX N/A
- CANF N/A
- EPS Growth
- CRNX N/A
- CANF N/A
- EPS
- CRNX N/A
- CANF N/A
- Revenue
- CRNX $1,039,000.00
- CANF $674,000.00
- Revenue This Year
- CRNX $356.40
- CANF $461.72
- Revenue Next Year
- CRNX $700.38
- CANF N/A
- P/E Ratio
- CRNX N/A
- CANF N/A
- Revenue Growth
- CRNX N/A
- CANF N/A
- 52 Week Low
- CRNX $24.10
- CANF $1.22
- 52 Week High
- CRNX $62.53
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CRNX 46.89
- CANF 37.12
- Support Level
- CRNX $28.75
- CANF $1.22
- Resistance Level
- CRNX $30.46
- CANF $1.82
- Average True Range (ATR)
- CRNX 2.19
- CANF 0.13
- MACD
- CRNX 0.27
- CANF -0.02
- Stochastic Oscillator
- CRNX 60.51
- CANF 3.13
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).